Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

procaps s.a. - colÁgeno hidrolizado - colÁgeno hidrolizado....10.0000 g. / Ácido ascÓrbico (vitamina c)....500 mg. / vitamina d3....1000 u.i. / beta-hidroxi-beta metilbutirato de calcio....2.52 g. / glicerofosfato de magnesio....80 mg.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

procaps s.a. - colÁgeno hidrolizado - colÁgeno hidrolizado....10.0000 g. / Ácido ascÓrbico (vitamina c)....500 mg. / vitamina d3....1000 u.i. / beta-hidroxi-beta metilbutirato de calcio....2.52 g. / glicerofosfato de magnesio....80 mg.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - sodium phenylbutyrate, quantity: 483 mg/g - granules - excipient ingredients: povidone; ethylcellulose; hypromellose; macrogol 1500; sucrose; hydrolysed maize starch - pheburane (sodium phenylbutyrate) is indicated for the management of hyperammonaemia associated with urea cycle disorders. pheburane? should be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, and protein-free calorie supplements)

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

United States - English - NLM (National Library of Medicine)

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 500 mg - sodium phenylbutyrate tablets is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, ne

United States - English - NLM (National Library of Medicine)

horizon therapeutics usa, inc. - glycerol phenylbutyrate (unii: zh6f1vcv7b) (glycerol phenylbutyrate - unii:zh6f1vcv7b) - glycerol phenylbutyrate 1.1 g in 1 ml - ravicti is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (ucds) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). limitations of use: - ravicti is not indicated for the treatment of acute hyperammonemia in patients with ucds because more rapidly acting interventions are essential to reduce plasma ammonia levels. - the safety and efficacy of ravicti for the treatment of n -acetylglutamate synthase (nags) deficiency has not been established. ravicti is contraindicated in patients with known hypersensitivity to phenylbutyrate. signs of hypersensitivity include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. risk summary limited available data with ravicti use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. in an animal reproduction study, administration of oral glycerol phenylbutyrate to pregnant rabbits during organogenesis at doses up to 2.7–times the dose of 6.87 ml/m2 /day in adult patients resulted in maternal toxicity, but had no effects on embryo-fetal development. in addition, there were no adverse developmental effects with administration of oral glycerol phenylbutyrate to pregnant rats during organogenesis at 1.9 times the dose of 6.87 ml/m2 /day in adult patients; however, maternal toxicity, reduced fetal weights, and variations in skeletal development were observed in pregnant rats administered oral glycerol phenylbutyrate during organogenesis at doses greater than or equal to 5.7 times the dose of 6.87 ml/m2 /day in adult patients [ see data] . report pregnancies to horizon at 1-866-479-6742. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data oral administration of glycerol phenylbutyrate during the period of organogenesis up to 350 mg/kg/day in rabbits produced maternal toxicity, but no effects on embryo-fetal development. the dose of 350 mg/kg/day in rabbits is approximately 2.7 times the dose of 6.87 ml/m2 /day in adult patients, based on combined area under the plasma concentration-time curve [aucs] for pba and paa. in rats, at an oral dose of 300 mg/kg/day of glycerol phenylbutyrate (1.9 times the dose of 6.87 ml/m2 /day in adult patients, based on combined aucs for pba and paa) during the period of organogenesis, no effects on embryo-fetal development were observed. doses of 650 mg/kg/day or greater produced maternal toxicity and adverse effects on embryo-fetal development including reduced fetal weights and cervical ribs at the 7th cervical vertebra. the dose of 650 mg/kg/day in rats is approximately 5.7 times the dose of 6.87 ml/m2 /day in adult patients, based on combined aucs for pba and paa. no developmental abnormalities, effects on growth, or effects on learning and memory were observed through maturation of offspring following oral administration in pregnant rats with up to 900 mg/kg/day of glycerol phenylbutyrate (8.5 times the dose of 6.87 ml/m2 /day in adult patients, based on combined aucs for pba and paa) during organogenesis and lactation. risk summary there are no data on the presence of ravicti in human milk, the effects on the breastfed infant, or the effects on milk production. because of the potential for serious adverse reactions, including neurotoxicity and tumorigenicity in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with ravicti. patients 2 years to 17 years of age the safety and effectiveness of ravicti in patients 2 years to less than 18 years of age have been established in 3 clinical studies: 2 open-label, fixed-sequence, switchover clinical studies from sodium phenylbutyrate to ravicti, and 1 long-term, open label safety study [see adverse reactions (6.1), clinical studies (14.2)] . patients less than 2 years of age the safety and effectiveness of ravicti in patients with ucds less than 2 years of age have been established in 3 open-label studies. pharmacokinetics and pharmacodynamics (plasma ammonia), and safety were studied in 17 patients aged 2 months to less than 2 years of age and in 16 patients less than 2 months of age [see adverse reactions (6.1), clinical studies (14.3)] . juvenile animal toxicity data in a juvenile rat study with daily oral dosing performed on postpartum day 2 through mating and pregnancy after maturation, terminal body weight was dose-dependently reduced by up to 16% in males and 12% in females at 900 mg/kg/day or higher (3 times the dose of 6.87 ml/m2 /day in adult patients, based on combined aucs for pba and paa). learning, memory, and motor activity endpoints were not affected. however, fertility (number of pregnant rats) was decreased by up to 25% at 650 mg/kg/day or higher (2.6 times the dose of 6.87 ml/m2 /day in adult patients, based on combined aucs for pba and paa). clinical studies of ravicti did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently than younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. the efficacy and safety of ravicti in patients with renal impairment are unknown. monitor ammonia levels closely when starting patients with impaired renal function on ravicti. no studies were conducted in patients with ucds and hepatic impairment. because conversion of paa to pagn occurs in the liver, patients with hepatic impairment may have reduced conversion capability and higher plasma paa and paa to pagn ratio [see clinical pharmacology (12.3)] . therefore, dosage for patients with moderate to severe hepatic impairment should be started at the lower end of the recommended dosing range and should be kept on the lowest dose necessary to control their ammonia levels [see dosage and administration (2.5)] .

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone butyrate - unii:05rmf7ypwn) - hydrocortisone butyrate 1.0 mg in 1 g - hydrocortisone butyrate cream usp, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - hydrocortisone butyrate solution, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. none.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - hydrocortisone butyrate cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. none.